Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Evaluate the Safety and Tolerability of Subcutaneous Injection of STP705 in Adult Subjects Undergoing Abdominoplasty

Trial Profile

A Phase 1 Study to Evaluate the Safety and Tolerability of Subcutaneous Injection of STP705 in Adult Subjects Undergoing Abdominoplasty

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs STP 705 (Primary)
  • Indications Skin disorders
  • Focus Adverse reactions; Proof of concept
  • Sponsors Sirnaomics

Most Recent Events

  • 15 Mar 2024 Status changed from active, no longer recruiting to completed.
  • 05 Feb 2024 According to a Sirnaomics media release, company presented latest developments and positive data from phase I study of STP705 for focal fat reduction (FFR)at IMCAS World Congress 2024, took place in Paris from February 1st - 3rd, 2024.
  • 01 Nov 2023 According to a Sirnaomics media release, company announced a poster with positive clinical data of STP705 for focal fat reduction (FFR) was presented at the 2023 Fall Clinical Dermatology Conference, which took place October 22 25 in Las Vegas.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top